Arvinas to present ARV-102 biomarker data at Parkinson's congress

Arvinas said it will present novel biomarker data from the Phase 1 clinical trial for ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders.